Rup Jyoti Sarma

Consultant Medical & Hemato oncologist, MOC Malad, Internal medicine, Alumnus Tata memorial hospital (Mumbai),

[BG Lab @OncologyBGLab]

A periodic reminder- https://t.co/7uJPhO29Zb

[Rup Jyoti Sarma @rupMedOnc]

Finally something to cherish about in PDAC after decades of result.

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Rup Jyoti Sarma @rupMedOnc]

@SuyogCancer @ASCO The kind of curves every medical oncologist wants to fall in love with. Cudos to the investigators !

[Eric K. Singhi, MD @lungoncdoc]

7yr CROWN update of 1L lorlatinib

55% progression-free at 7 YEARS.
Median PFS STILL not reached.

In metastatic solid tumors, this is essentially unheard of. Let that sink in.

And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26

[Vanita Noronha, MBBS MD DM @VanitaNoronha]

Proud to share ph III RCT on low-dose abiraterone (250 mg w/food) vs std-dose abi in CRPC.
Despite markedly lower drug exposure, low-dose abi had comparable efficacy, safety & QoL: supporting affordable and practical treatment https://t.co/hHmmLxM4hl
#ProstateCancer @OncoAlert

[anand mahindra @anandmahindra]

The results of the recent state elections have been dramatic by any measure.

But for me, this image will remain the most unforgettable outcome of the elections.

More than 166,000 votes were cast between the two leading candidates in this constituency in Tamil Nadu.

And history was changed by just one vote.

This image should be shown in every school in the country & perhaps around the world.

So that every child understands that when they grow up, the greatest power they may possess is the Power of One.

The power of their one vote.

[Vincent Rajkumar @VincentRK]

Clinical trials:
Easy to criticize. Hard to do.

[Vincent Rajkumar @VincentRK]

Many leaders in medicine are focused on AI and how it’s going to solve problems in medicine. Maybe.

But doctors with great clinical acumen, empathy, and the wisdom to make the right judgment call are the ones we need more of, and who patients want and seek out. This is the important stuff.

[Rup Jyoti Sarma @rupMedOnc]

The power of precision oncology

[Papa Heme @Papa_Heme]

Targeted therapies in AML. So many!

FLT3 mutation = gilteritinib, midostaurin, quizartinib
IDH1 mutation = ivosidenib, olutasidenib
IDH2 mutation = enasidenib
KMT2A rearrangement = revumenib
NPM1 mutatuion = revumenib, ziftomenib
CD33 = gemtuzumab ozogamicin
BCL2 = venetoclax

[Rup Jyoti Sarma @rupMedOnc]

Very few instances of accelerated approval of a 1L therapy based on a single arm trial!

[Oncology Brothers @OncBrothers]

Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72)

- ORR: 76%
- Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response
- New SoC

#lcsm #LungCancer #OncTwitter

[Rup Jyoti Sarma @rupMedOnc]

The power of precision oncology. We have miles to go..

[Yüksel Ürün @DrYukselUrun]

BRCAAway final OS update.

Front-line combination mattered.
Sequential therapy did not catch up.

Phase 2.
But a clear signal.

Test early.
Treat early.

#gu26 #cancer #oncology
@oncoalert @ASCO @medicalwatchBC
@DrChoueiri @yekeduz_emre @neerajaiims @CParkMD @Silke_Gillessen @PGrivasMDPhD @VivekSubbiah @TwoOncDocs @OncBrothers @Larvol @nataliagandur @montypal @crisbergerot @DrDanielHeng @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1 @tompowles1 @BraunMDPhD @uromigos @MattGalsky @apolo_andrea
@bavilima @SuyogCancer @ONCOassist @gbanna74 @NazliDizman @MedicalwatchFTW @OncLive @urologysummit @IMG_Oncologists @AmandaBinDC @sarah_c_hopkins @MikeSerzanMD

[Tata Memorial Centre @TataMemorialCtr]

85 years of care, compassion, and commitment.

Since 1941, @TataMemorial has remained dedicated to accessible cancer care, advancing research, and training the next generation of oncology professionals.

Honouring the legacy. Renewing the commitment.
#85YearsOfCare #FoundationDay

[Pramesh CS @cspramesh]

India’s rollout of the cervical cancer (HPV) vaccine is truly a landmark prevention policy. Cervical cancer is largely preventable, yet remains a leading cause of cancer deaths among women in India. 🧵(1/n)

[Rup Jyoti Sarma @rupMedOnc]

Is this a gefitinib kind of moment for solid oncology? Only time will tell- but we are hopefull to see an undruggable being targeted.

[NEJM @NEJM]

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: https://t.co/LBqROGlouc

Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors https://t.co/5Ox6Kuax6Q

[soria @jsoriamd]

🧬🛡️ HER2-low tumors escape HER2 ADCs by losing the target
• True HER2 loss is uncommon in HER2-amplified disease but frequent in HER2-low, where HER2 isn’t oncogenic
• On HER2 ADC therapy, ~50% of tumors reduce HER2; among reducers, ~half become IHC 0
• Reduced HER2 → impaired ADC internalization, not payload resistance
• ERBB2 ECD variants disrupt antibody binding and phenocopy antigen loss
• Suggested strategy: multi-target payload delivery to bypass target dependence and improve durability
https://t.co/fAFUEr3V3p

[Yakup Ergün @dr_yakupergun]

Premenopausal HR+/HER2+ eBC – Adjuvant ET

• RD after NAT → OFS + AI
• pCR after NAT → risk-adapted
 – Stage III → OFS + AI
 – Stage I–II → AI or TAM ± OFS
• Upfront surgery → baseline stage-driven ET

Principle:
RD = ER-dependent, chemo-resistant → needs ET intensification

Great editorial👇

https://t.co/AuDXPhHDoi

[Toni Choueiri, MD @DrChoueiri]

JUST IN: The report we always look for every year: CANCER STATISTICS, 2026

New milestone with 5y Survival of 70%!!! Still a lot of room to improve but also excellent progress !

@AmericanCancer @CACancerJournal @DanaFarber

https://t.co/ZtFDhFOGgU

[Rup Jyoti Sarma @rupMedOnc]

Congratulations to @AdityaDharFilms. You have set a new benchmark in Bollywood. Not a single boring minute in a 3.5 hrs movie! Cudos 👏

#Dhurandhar

[Rup Jyoti Sarma @rupMedOnc]

It’s a wonderfully immersive read, one that makes you feel as if you’re strolling through the streets of Rome. The author navigates the complexities of immigration and its impact on society with remarkable depth and elegance.

[Rup Jyoti Sarma @rupMedOnc]

I’m fascinated by this book! The author’s passion is truly inspiring — she learned an entirely new language simply because she wanted to, then went on to write books in that second language and translate them back into her first.